This afternoon we watched Guardant Health drop -3.9% to a price of $54.58 per share. The Mid-Cap Medical Specialities company is now trading -11.9% below its average target price of $61.95. Analysts have set target prices ranging from $47.0 to $70.0 per share for Guardant Health, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 6.8%, and a short ratio of 2.59. Since 4.5% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.1% of Guardant Health's shares being owned by this investor type.
Institutions Invested in Guardant Health
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 10% | 12,168,020 | $664,130,553 |
| 2025-06-30 | Blackrock Inc. | 9% | 10,979,470 | $599,259,492 |
| 2025-06-30 | Capital International Investors | 4% | 4,976,458 | $271,615,086 |
| 2025-06-30 | BAILLIE GIFFORD & CO | 4% | 4,809,786 | $262,518,128 |
| 2025-06-30 | Deep Track Capital, Lp | 3% | 4,250,000 | $231,965,007 |
| 2025-06-30 | Invesco Ltd. | 3% | 3,558,501 | $194,222,991 |
| 2025-06-30 | Eventide Asset Management LLC | 3% | 3,458,963 | $188,790,206 |
| 2025-06-30 | Cadian Capital Management, LP | 3% | 3,179,217 | $173,521,669 |
| 2025-06-30 | Citadel Advisors Llc | 2% | 2,938,553 | $160,386,228 |
| 2025-06-30 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2% | 2,933,988 | $160,137,070 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Guardant Health.
